SynthesisFrontiers in oncology2025
Fracture risk and survival outcomes of radium-223 therapy for bone metastases in mCRPC and the modulatory role of bone-protective therapy: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metastatic castration-resistant prostate cancer (mCRPC) frequently involves the skeleton. While Radium-223 (Ra-223) alleviates symptomatic bone lesions, its effect on overall survival (OS) and fracture risk is debated. Bone-protective agents (BPAs) may play a critical modulatory role. This study systematically examined how Ra-223 influences OS and fracture risk and the effect of concomitant BPA use. Methods: As per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, PubMed, Embase, the Cochrane Library, and Web of Science were retrieved for randomized controlled trials (RCTs) and cohort studies through July 14, 2025. The primary outcomes were OS and fracture incidence in this PROSPERO-registered review (Registration No.: CRD420251102769). Hazard ratios (HRs) with 95% confidence intervals (CIs) were preferentially extracted; relative risks (RRs) were used when necessary. Heterogeneity was assessed using the I² statistic to guide the choice of random-effects versus random-effects models. Leave-one-out sensitivity analyses were conducted, and study quality was appraised using the NIH tool for RCTs and the Newcastle-Ottawa Scale (NOS) for cohort studies. Results: Nine studies were included, including six RCTs and three cohort studies. The pooled OS analysis (five studies, n=3,671) showed no significant benefit (HR = 0.82, 95% CI: 0.60-1.11; I²=79.8%). Excluding one study on an abiraterone background revealed a survival advantage (HR = 0.71, 95% CI: 0.61-0.81; I²=43.5%). For fracture risk, pooled analysis (five studies, n=3,671) showed no significant increase (HR = 1.32, 95% CI: 0.68-2.58; I²=89.1%). Concomitant BPA use (3 studies, n=279) was associated with a substantial fracture risk reduction (RR = 0.23, 95% CI: 0.11-0.45; I²=0.0%). Conclusions: Current evidence suggests that Ra-223 administered alongside standard therapy is not associated with statistically significant differences in OS or fracture risk among patients with mCRPC. Concomitant BPA therapy significantly reduces fracture incidence. Therapeutic context, including concurrent therapies and sequencing, may influence survival. Routine evaluation and consideration of BPA use during Ra-223-based regimens, together with strengthened bone health monitoring protocols, are advisable. Given the limited number of eligible studies and substantial heterogeneity, additional high-quality RCTs and individual patient data meta-analyses are needed to clarify these associations. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251102769.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.